Osteoporosis Drugs Market Share, Global Insights And Gross Margin Analysis 2020-2023

 Market Scenario:

Osteoporosis is weakening of bones due to lower bone mass resulting in and micro-architectural deterioration of bone tissue and subsequent higher risk of a broken fracture. It generally occurs at an advanced age and women are more susceptible to it than males by about three to four folds. WHO estimates that around 1.66 million hip fractures occur each year worldwide due to osteoporosis. According to national osteoporosis foundation about 54 million Americans suffer from osteoporosis.

The disease also has a genetic bias in that it Caucasians are more affected than Asians. The disease prevalence is lowest in African population.

The market driving factors were identified to be rise in the geriatric population, increased screening, drug induced osteoporosis, alcoholism and smoking, increased awareness and focus towards female health, rising prevalence of diseases, conditions and medical procedures that may cause bone loss such as cancer, autoimmune disorders, thalassemia, hormonal disorders, modern lifestyle etc.

The market restraints are loss of patents of block busters, greater penetration of generics and fragmentation of market, poor efficacy and side effects of present therapies, non-life threatening nature and poor symptoms of osteoporosis etc.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2479

Taking all the factors into consideration, we expect the global osteoporosis market which totaled ~ $10,855 million to reach 14,300 million by 2022, growing with a CAGR of 4.7%.

 

Study Objectives Global Osteoporosis Drugs Market:

• To provide detail analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the global osteoporosis drugs market
• To provide insights about factors affecting the market growth
• To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
• To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
• To provide country level analysis of the market with respect to the current market size and future prospective
• To provide country level analysis of the market for segments by drug class (bisphosphonates, calcitonins, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others), by route of administration (oral, injectable and others) and by gender (male, female and children).
• To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.

Key Players for Global Osteoporosis Drugs Market:
Some of the key players in this market are: Eli Lilly and Company, Merck & Co., Novartis International AG, Amgen Inc., F. Hoffmann La Roche Ltd., Pfizer Inc., Novo Nordisk, Teva Pharmaceutical Industries Ltd. and others.

Segments:
Global osteoporosis drugs market has been segmented on the basis of drug class which comprises bisphosphonates, calcitonin’s, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others. On the basis of route of administration; market is segmented into oral, injectable and others. On the basis of gender the market is segmented into male and female.

Intended Audience:

• Osteoporosis Drugs Manufacturers
• Osteoporosis Drugs Suppliers
• Private Research Laboratories
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Government Research Laboratories
• Contract Manufacturing Organizations

Regional Analysis of Global Osteoporosis Drugs Market:
Globally America is the largest market for osteoporosis drugs. Europe is the second-largest market for osteoporosis drugs. The developed regions are expected to hold their market leadership in the near future but with falling market share due to rise of Asia Pacific region which is expected to be fastest growing region in osteoporosis drugs market. The Asia pacific region will be led by China and India. Africa is expected to be a laggard in the global osteoporosis market.

The report for Global Osteoporosis Drugs Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/osteoporosis-drugs-market-2479

Anti-viral drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, And Forecast 2020 - 2023

 Market Scenario:

The rising cases of viral disease is identified to boost the global anti-viral drugs market growth. The inadequacy of dietary nutrition in people, due to increase in consumption of high calorie and low fibrous food is creating favourable condition for virus to invade human body. Hence, the need for anti-viral drugs are surging as viral infections prevail. The growing incidences of HIV and other sexually-transmitted diseases are also boosting the sales number of anti-viral drugs, hence, anticipated to prompt the anti-viral drug market growth.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2454

The increase in cases of drug resistance is propelling extensive research and developmental undertakings for launching more effective anti-viral drugs. Additionally, the stringency in drug approval stages are taking care of the quality of drugs in the pipeline. New product launches are gaining traction for revenue generation for the anti-viral drugs market. The application of anti-viral drugs in other diseases like, bird flu, and others is also likely to prompt the global anti-viral drug market growth.

The expiry of patents for certain blockbuster anti-viral drug are stimulating generic drug competition in the anti-viral drug market. This is deepening the competitive scenario of the global anti-viral drug market over the assessment period.

However, adverse effects of anti-viral drugs and high price of anti-viral drugs can hinder the anti-viral drugs market growth over the assessment period. 

Key Players

MRFR have enlisted some of the prominent Anti-viral drugs Market Companies operating in the anti-viral drugs market. They are; Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Gilead Sciences Inc., Cipla Inc. GlaxoSmithKline Plc, Novartis International AG, Abbott Laboratories, and  Astra Zeneca AB. 

Market Segmentation:

Global anti-viral drugs market has been segmented on the basis of on the basis of application, which comprises hepatitis, HIV/AIDS, herpes, influenza and others. On the basis of mechanism of action; market is segmented into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors and others.

Regional Analysis:

Depending on geographic region, anti-viral drugs market is segmented into four key regions: America, Europe, Asia Pacific, and Middle East & Africa. Globally, America is the largest market for anti-viral drugs with Europe tied for the second space. Asia Pacific region is expected to be fastest growing region in anti-viral drugs market. 

Access More Details of the Report @  https://www.marketresearchfuture.com/reports/anti-viral-drugs-market-2454 

Worldwide Cerebrospinal Fluid Management Devices Market 2019 Synopsis With Leading Players, Industry Growth Factor Foresight By 2023

 Market scenario

Rising cases of hydrocephalus is one of the key factors driving the cerebrospinal fluid management (CSF) devices market. According to the Brain Foundation, one in every 1,000 Australian children is born with hydrocephalus annually.

Global cerebrospinal fluid management (CSF) devices market is expected to grow significantly over the forecast period. It is projected to grow at a CAGR of 4.5% over the forecast period.

Various other factors such as rising research & development expenditure, geriatric population, technological advancements, growing adoption of minimally invasive procedures, and rising awareness about hydrocephalus are also expected to propel the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7196

However, lack of trained professionals, side-effects associated with the treatment, and high cost of devices can hinder the market growth over the forecast period.

Key players

Medtronic plc, Integra LifeSciences Holdings Corporation, B. Braun Melsungen AG, DePuy Synthes, Spiegelberg GmbH & Co. KG, SOPHYSA, Natus Medical Incorporated, Dispomedica GmbH, Delta Surgical Limited, Argi Grup, Moller Medical GmbH, G. SURGIWEAR LTD., Wellong Instruments Co., Ltd., BeckerSmith Medical, Inc., and others.

Segmentation

The Global cerebrospinal fluid management (CSF) devices market is segmented based on product, age group, end user, and region.

The Global market for cerebrospinal fluid management (CSF) devices, by product is segmented into shunts, valve, and external drainage systems.

The shunts segment is further classified as ventriculoperitoneal (VP), ventriculoatrial (VA), lumboperitoneal (LP), and ventriculopleural (VPL). The valve segment is further classified as fixed, and adjustable. The external drainage systems segment is further classified as external ventricular drainage (EVD) systems, and lumbar drainage (LD) systems.

Based on age group, the market is segmented into paediatric, adult, and geriatric.

Based on end user, the market is segmented into hospitals, ambulatory settings, clinics, research and academic institutes, and others.

In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.

The cerebrospinal fluid management (CSF) devices market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European cerebrospinal fluid management (CSF) devices market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The cerebrospinal fluid management (CSF) devices market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cerebrospinal fluid management (CSF) devices market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

The Americas dominated the global market for cerebrospinal fluid management (CSF) devices owing to the rising geriatric population and presence of major market players. As per the 2018 statistics suggested by the U.S. Census Bureau, by 2035, there will be 78 million people 65 years and older compared to 76 million under the age of 18.

In 2017, it was estimated that Europe stood second in the global cerebrospinal fluid management (CSF) devices market. This can be attributed to the rising research and development investments and increasing technological advancements.

Asia Pacific was projected to be the fastest growing region in 2017. Increasing healthcare expenditure and rising cases of hydrocephalus drives the regional markets of the Asia Pacific region. According to the Hydrocephalus association, approximately 200,000 cases of congenital hydrocephalus in infants are registered around the world. However, in India, nearly 12,000 cases of congenital hydrocephalus are registered each year.

On the other hand, the Middle East and Africa held least cerebrospinal fluid management (CSF) devices market share in global market due to the low per capita income and stringent government policies, especially within the African region.

Browse More Report Details @ https://www.marketresearchfuture.com/reports/cerebrospinal-fluid-management-devices-market-7196

Amyotrophic Lateral Sclerosis Industry Overview By Growth Factors, Product Chain Value, Competitors Analysis And Forecast 2023

 Market Scenario

Market Research Future presents report by By Type (Familial ALS), by Treatment (Medication, Physical Therapy, Speech Therapy), by Diagnosis (Laboratory Tests, Imaging Tests), End-User (Hospitals, Specialty Centers) and Global forecast till 2023

ALS or Amyotrophic Lateral Sclerosis is a neurological ailment which affects the nerve cells in the spinal cord and the brain that controls the voluntary muscles’ activities. Some of the common symptoms of ALS include cramps, muscle weakness, respiratory problems, and fasciculation. This is a progressive neurological disease where gradually patients become dependent on physicians and caregivers increasingly. Often ALS results in respiratory failure as the patient loses the ability of controlling the muscles both in the diaphragm and the chest. Ultimately, it turns fatal.

Additional factors such as the inclination towards the sedentary lifestyle are driving the market growth and increasing the risk of developing ALS. Besides, the increasing geriatric population substantiates market growth, creating a demand for symptomatic and targeted treatment options.

The Global Amyotrophic Lateral Sclerosis Treatment Market size by valuation is expected to surpass USD 841.6 million by 2023, growing at approximately 7.89 % CAGR over the forecast period (2019-2023). In 2017, the market had a valuation of USD 526 million.

But the high cost of the treatment of ALS may hinder the market growth over the forecast period.

Segments                                                                                                                                            

The Global amyotrophic lateral sclerosis market has been segmented on the basis of type, treatment, and end-user.

By type, the market is segmented into sporadic and familial ALS. The sporadic ALS, also abbreviated as SALS, was the largest segment in 2017 and can dominate the market over the forecast period.

By treatment, the amyotrophic lateral sclerosis market has been segmented into medication, physical therapy, respiratory therapy, speech therapy, and others. Out of these, medication had the largest market in 2017.

By end-user, the ALS market has been segmented into hospitals, specialty centers, research & academic institutes, and others. Among these, the subsegment Hospital accounts for the largest segment.

Regional Analysis

By Regions, the global amyotrophic lateral sclerosis market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.

 

The Americas is estimated to dominate the global ALS market owing to the increasing pool of awareness and the rising prevalence of hypertension. ALS remains a significant public health challenge in the US. Therefore, governments and private non-profit organizations are developing specific guidelines for the management and treatment of ALS. Public and private organizations are involved in strategic partnerships and collaborations in search for a better outcome in the research of amyotrophic lateral sclerosis treatment in the region.

 

The amyotrophic lateral sclerosis market in the European region stands at the second position in terms of the market size mainly due to the well-established healthcare sector. Several companies and research institutes are also establishing advanced facilities to research ALS.

 

Moreover, in recent years, there has been an increase in the adoption of sedentary lifestyles among people. Research shows that an increase in physical activities such as exercise helps in reducing the pain and thwarting some of the symptoms such as loss of motion in patients who have ALS.

 

Thus, the inclination towards the sedentary lifestyle increases the risk of developing ALS among the elderly population, thus creating a demand for symptomatic and targeted treatment options. The development of novel therapeutic approaches and advanced treatment options are likely to push the growth of the amyotrophic lateral sclerosis market during the forecast period.

 

Whereas, the ALS market in the Asia Pacific region is expected to grow rapidly due to the increasing prevalence of the disease and rapidly developing healthcare infrastructure. The increasing economy in the region is playing a vital role in the growth of the market. Furthermore, the increase in the setups of research and development centers also fuels the growth of the ALS market in the region.

Key Players                                                                                                         

• Sun Pharmaceutical (India),
• Mitsubishi Tanabe Pharma America (U.S.),
• Biogen (U.S.),
• Sanofi (France),
• Mylan N.V. (U.S.),
• Covis Pharma (Switzerland),
• Ionis Pharmaceutical (U.S.),
• ITF Pharma (U.S.),
• Ascend Pharmaceuticals LLC (U.S.),
• Apotex Inc. (Canada).

Feb 2019- Leading technology transfer company, BGN Technologies has lately disclosed about a new AI (artificial intelligence) platform to monitor and predict the development of neurodegenerative diseases in order to identify markers both for improved drug development and personalized patient care. This technology will focus on ALS at an initial stage and later on will be adapted to other neurodegenerative diseases namely Alzheimer’s and Parkinson’s. The latest technology will predict disease progression more accurately, a key component for clinical trials along with better identifying the interrelationships amid demographics and many other measurable factors that are identified through patient functionality and physical examinations. It will allow researchers in creating a system which insurers, HMOs, pharmaceutical companies, caregivers, physicians, and patients can use on mobile applications and desktop for monitoring and predicting ALS progression.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/amyotrophic-lateral-sclerosis-market-5822

Rectovaginal Fistula Market Shares Analysis, Key Development Strategies And Forecasts Till 2023

 Market Scenario

As per the Birth Injury Guide, estimates show that between 700 and 900 women die every year due to pregnancy or childbirth-related complications in United States.

Additionally, the growing research and development expenditure by the government as well as private sector is likely to contribute to the market growth. However, the high cost of surgery may restraint the market trends growth during the assessment period.  

Due to increasing focus on research and development in treatment of diseases, moreover increasing applications in cancer treatment are the factors responsible to boost the market growth during assessment period. Companies are using a Rectovaginal Fistula market trends of strategic alliance and acquisition to gain the market and minimize the competition in the market.

The Global Rectovaginal Fistula Market held a market value of USD 950 million in 2017 and is projected to grow at a CAGR of 5.4% over the forecast period. 

Key players

Some of the prominent players in the global rectovaginal fistula market are Cook Medical, Takeda Pharmaceutical Company, Johnson & Johnson Services Inc., Pfizer Inc., Allergan, AbbVie Inc, Novartis International AG, Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche, Eli Lilly and Company, GlaxoSmithKline plc, Sanofi S.A, and others

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7138

Segmentation

The global rectovaginal fistula market has been segmented into diagnosis, treatment, and end user.

Based on treatment, the market has been segmented into medications and surgery. Medications is further segmented into antibiotics and infliximab. Rectovaginal Fistula Surgery is further segmented into sewing an anal fistula plug or patch of biologic tissue into the fistula, using a tissue graft, repairing the anal sphincter muscles, performing a colostomy before repairing a fistula in complex or recurrent cases.

By diagnosis, the market has been segmented into physical exam, contrast tests, blue dye test, computerized tomography (CT) scan, magnetic resonance imaging (MRI), anorectal ultrasound, anorectal manometry, and others.

The rectovaginal fistula market, by end user, has been segmented into hospitals & clinics, diagnostic centres, academic institutions and research organizations, and others.

The global rectovaginal fistula market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rectovaginal fistula market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.         

The European rectovaginal fistula market has been segmented into Western Europe and Eastern Europe. The Western Europe rectovaginal fistula market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.      

The rectovaginal fistula market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rectovaginal fistula market in the Middle East & Africa has been segmented into the Middle East and Africa.       

Regional Market Summary

On regional basis, the Americas is anticipated to dominate the global rectovaginal fistula market owing to the growing R&D budgets by both government as well as commercial pharmaceutical and biotechnological companies and increasing adoption of advanced technologies in the region.  Europe is expected to hold the second largest position in the global rectovaginal fistula market owing to the presence of strong academic & research base and availability of funding for research in the European countries. Asia Pacific has served an opportunity for rectovaginal fistula market in this region due to increasing demand for the better treatment and devices and increasing prevalence of disease like cancer. The Middle East & Africa has the least share of the global rectovaginal fistula market. Moreover, the major market share of the region is expected to be held by the Middle East region owing to the increasing government initiatives for the healthcare sector.   

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/rectovaginal-fistula-market-7138

Pedicle Screw Systems Market Professional Overview 2019-2023 With Major Vendors Size, Shares And Worldwide Demand

 Market Scenario:

Pedicle screw system are the instruments that are used in spinal surgery to stop the pain caused by joints owing to disease. These screws are used in the lumbar spine for more complex anatomy such as the thoracic and thoracolumbar level. The pedicle screw allows stability in spinal arthrodesis and provide three column control over the spinal elements for improving deformation.

The Global Pedicle Screw Systems Market is accounted for USD 506.65 million in 2017 and expected to register ~ 6.3 % CAGR during the forecast period (2018–2023).

The rising prevalence of arthritis, increasing incidence of spinal cord injuries, aging population, and growing preference of minimally invasive surgeries are expected to drive the growth of the market. Moreover, rising R&D spending and aggressive strategies adopted by the top players such as new product launches are contributing to the growth of the market. For instance, in September 2018, Nvision Biomedical Technologies, LLC launched the pedicle screw system focus at North American Spine Society (NASS).

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7081

The high cost associated with pedicle screw systems, Sluggish product approval processes and strict regulatory frameworks may hamper the growth of the market during the assessment period.

Segmentation:

The Global Pedicle Screw Systems Market has been segmented on the basis of surgery type, product type, indication, application, and end user.

On the basis of surgery type, the market has been classified as open surgery and minimally invasive surgery. The market, by product type, has been segmented into polyaxial pedicle screw systems, monoaxial pedicle screw systems, and others. Based on indication, the market has been segmented into spinal degeneration, spinal trauma, spinal deformities, and others. The market, by application, has been segmented into thoracolumbar fusion and spinal cervical fusion. On the basis of end user, the market has been classified as hospitals and clinics, research organization and academic institute, and others. The polyaxial pedicle screw systems segment is expected to hold the largest market share of the pedicle screw systems market, by product type, during the forecast period. Also, minimally invasive surgery to register the highest CAGR in the global pedicle screw systems market during the forecast period.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The pedicle screw systems market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European pedicle screw systems market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The pedicle screw systems market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The pedicle screw systems market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary:

The Americas are likely to dominate the global pedicle screw systems market owing to the rising prevalence of spinal disorders, increasing geriatric population, and rising in FDA approved pedicle screws. According to the report published by Centers for Disease Control and Prevention (CDC), in 2016, 5.1% of men of 65 years and over are suffering with lumbar spine in United States. Also, 24.5% of women 65 years of age and over have lumbar spine in United States.

The European market is expected to be the second-largest pedicle screw systems market. The market growth in this region can be attributed to the government support for research & development and availability of funds for research.

Asia-Pacific is expected to be the fastest-growing pedicle screw systems market during the forecast period owing to the rising number of the orthopedic surgeries, rising investments in healthcare and expansions by market players in the region. Moreover, country such as India and China are considering fastest growing region due to the presence of huge patient population. Moreover, the government of these countries are open to adopt new technology, and best treatment option from a developed country. According to the report published by OMICS International, in 2017, around 500,000 to 600,000 spinal surgery had performed in China.

The market in the Middle East & Africa is expected to account for the smallest share of the global pedicle screw systems market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Key Players:

Some of the key players in the global pedicle screw systems market are Alphatec Spine, Inc., Amedica Corporation, B. Braun Melsungen AG, Depuy Synthes, Globus Medical, Inc., K2M Group Holdings, Inc., Medtronic PLC, Nvision Biomedical Technologies, LLC., Orthofix International N.V., RTI Surgical, Inc., SeaSpine, Stryker Corporation, Zimmer Biomet Holdings, Inc.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/pedicle-screw-systems-market-7081

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Oncology Information Systems Market Report By Global Industry Trends And Forecast The Upcoming Opportunities And Demand Till 2023

 Market Scenario

Global Oncology Information Systems (OIS) Growth is expected to register a healthy CAGR over the forecast period. The market held a market value of USD 2,356.6 million in 2017 and is projected to grow at a CAGR of 7.5% during the forecast period.

Oncology Information Systems (OIS) is a comprehensive information and image management solution that facilitates the management of patient treatment schedules, treatment plans, treatment delivery, and treatment summaries. This system involves the exchange of information between radiation therapy departments and the healthcare enterprises. Factors attributed for the market growth are worldwide growing geriatric population along with rising prevalence of cancer, increasing investments in cancer research, and technological advancements in OIS. The International Agency for Research on Cancer (IARC) stated that there were 14 million new cases of cancer in 2012 that grew to 17.0 million in 2018, which is anticipated to reach to more than 22 million by 2030. Progress in developing treatments is enabling investors to invest in oncology research. Increasing equity investments in ca ncer-therapeutics startups is foreseen to shape the OIS vertical in the near future. On the contrary, higher costs associated with OIS services are anticipated to restrain the market growth over the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7080

Segmentation

The global oncology information systems market has been segmented into product & service type, application, and end user.

By product & service type, the market has been segmented into software and professional services. The software segment is further categorized into patient information systems and treatment planning systems. The professional services segment is further divided into consulting/optimization services, implementation services, and post-sale & maintenance services. The software for patient information systems segment spearheaded the market in 2017 as these systems offer advantages including planned treatment and remote access due to digital availability as compared to conventional record maintenance methods.

On the basis of application, the market has been classified into medical oncology, radiation oncology, and surgical oncology. The medical oncology segment would lead the market over the forecast period owing to rising applications of OIS in efficiently managing, interpreting, analyzing, and storing the patient information, as well as, in predicting the treatment results for patients, thereby improving their survival rates.

Based on end user, the market has been categorized into hospitals & oncology clinics, government institutes, and research centers.

The global oncology information systems market segmentation by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The oncology information systems market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European oncology information systems market has been segmented into Western Europe and Eastern Europe. The Western Europe oncology information systems market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The oncology information systems market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The oncology information systems market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

Accuray Incorporated, Cerner Corporation, Philips Healthcare, McKesson Corporation, Altos Solutions, Inc., Elekta AB, Varian Medical Systems, Inc., Flatiron Health, Inc., RaySearch Laboratories, Epic Systems Corporation, Bogardus Medical Systems, Inc., and CureMD Healthcare are some of the prominent players in the global oncology information systems market.

Regional Analysis

Geographically, the Americas would grab the highest market share over the forecast period due to the presence of oncology information systems providers, changing lifestyle coupled with rising burden of cancer, increasing expenditure on healthcare, and adoption of oncology information systems in the US and Canada. The IARC reported that in 2018, the Americas have 13.3% of the global population and accounted for 21.0% of incidence and 14.4% of mortality worldwide.

Asia-Pacific would represent the phenomenal growth during the forecast period due to growing elderly population coupled with rising prevalence of cancer. The World Health Organization (WHO) and IARC reported that the proportions of cancer deaths in Asia (57.3%) are higher than the proportions of incident cases (48.4%) due to the higher frequency of certain cancer types associated with poorer prognosis and higher mortality rates.

The oncology information systems market in the Middle East & Africa will exhibit considerable market growth rate from 2018 to 2023. Majority of the regional market is likely to govern by the Middle East region due to the presence of world-class cancer treatment centers in Dubai, Saudi Arabia, increasing healthcare sector reforms, and gradually rising investments in OIS sector.

Growing adoption of OIS in European countries, namely, UK, Germany, France, Italy, and Spain, as the major market value contributors such as Philips Healthcare, Elekta AB, and RaySearch Laboratories are headquartered in the region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/oncology-information-systems-market-7080